Reconstituted complexes of mycobacterial HSP70 and EBV LMP2A-derived peptides elicit peptide-specific cytotoxic T lymphocyte responses and anti-tumor immunity

Abstract Epstein–Barr virus (EBV) latent membrane protein 2A (LMP2A) is a subdominant antigen expressed in EBV-associated malignancies, such as Hodgkin's diseases (HD) and nasopharyngeal carcinoma. A large number of previous studies have described LMP2A as an ideal target antigen in immunothera...

Full description

Saved in:
Bibliographic Details
Published inVaccine Vol. 29; no. 43; pp. 7414 - 7423
Main Authors Liu, Genyan, Yao, Kun, Wang, Bing, Zhou, Feng, Chen, Yun, Li, Linyun, Chi, Jing, Peng, Guangyong
Format Journal Article
LanguageEnglish
Published Kidlington Elsevier Ltd 06.10.2011
Elsevier
Elsevier Limited
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Abstract Epstein–Barr virus (EBV) latent membrane protein 2A (LMP2A) is a subdominant antigen expressed in EBV-associated malignancies, such as Hodgkin's diseases (HD) and nasopharyngeal carcinoma. A large number of previous studies have described LMP2A as an ideal target antigen in immunotherapy of EBV-related diseases, while limited successes have been achieved in clinical trials. Mycobacterium tuberculosis heat shock protein 70 (MtHsp70) is known as an effective molecular adjuvant for protein- or epitope-based vaccines. In the present study, we reconstituted two chaperone complexes of MtHsp70 and LMP2A-derived peptides (LMP2A356–364 FLYALALLL and LMP2A426–434 CLGGLLTMV) in vitro . We then investigated LMP2A-specific immune responses induced by reconstituted complexes of MtHsp70 and LMP2A-peptides using both EBV infected healthy donor PBMCs and HLA-A2.1 transgenic mouse models. We found that reconstituted complexes of MtHsp70 and LMP2A-peptides significantly elicit LMP2A-specific IFN-γ-producing cells and rousted cytotoxic T lymphocytes (CTLs) in vitro and in vivo . In addition, LMP2A-specific immune responses induced by the reconstituted complexes of MtHsp70 and LMP2A-peptides mediated potently protective activity as well as therapeutic efficacy against LMP2A-expressed tumor challenge in mouse models. These studies provide new insights for the development of novel LMP2A-based vaccines against EBV-associated malignancies.
AbstractList Epstein-Barr virus (EBV) latent membrane protein 2A (LMP2A) is a subdominant antigen expressed in EBV-associated malignancies, such as Hodgkin's diseases (HD) and nasopharyngeal carcinoma. A large number of previous studies have described LMP2A as an ideal target antigen in immunotherapy of EBV-related diseases, while limited successes have been achieved in clinical trials. Mycobacterium tuberculosis heat shock protein 70 (MtHsp70) is known as an effective molecular adjuvant for protein- or epitope-based vaccines. In the present study, we reconstituted two chaperone complexes of MtHsp70 and LMP2A-derived peptides (LMP2A(356-364) FLYALALLL and LMP2A(426-434) CLGGLLTMV) in vitro. We then investigated LMP2A-specific immune responses induced by reconstituted complexes of MtHsp70 and LMP2A-peptides using both EBV infected healthy donor PBMCs and HLA-A2.1 transgenic mouse models. We found that reconstituted complexes of MtHsp70 and LMP2A-peptides significantly elicit LMP2A-specific IFN-γ-producing cells and rousted cytotoxic T lymphocytes (CTLs) in vitro and in vivo. In addition, LMP2A-specific immune responses induced by the reconstituted complexes of MtHsp70 and LMP2A-peptides mediated potently protective activity as well as therapeutic efficacy against LMP2A-expressed tumor challenge in mouse models. These studies provide new insights for the development of novel LMP2A-based vaccines against EBV-associated malignancies.
Epstein-Barr virus (EBV) latent membrane protein 2A (LMP2A) is a subdominant antigen expressed in EBV-associated malignancies, such as Hodgkin's diseases (HD) and nasopharyngeal carcinoma. A large number of previous studies have described LMP2A as an ideal target antigen in immunotherapy of EBV-related diseases, while limited successes have been achieved in clinical trials.Mycobacterium tuberculosisheat shock protein 70 (MtHsp70) is known as an effective molecular adjuvant for protein- or epitope-based vaccines. In the present study, we reconstituted two chaperone complexes of MtHsp70 and LMP2A-derived peptides (LMP2A356-364FLYALALLL and LMP2A426-434CLGGLLTMV)in vitro. We then investigated LMP2A-specific immune responses induced by reconstituted complexes of MtHsp70 and LMP2A-peptides using both EBV infected healthy donor PBMCs and HLA-A2.1 transgenic mouse models. We found that reconstituted complexes of MtHsp70 and LMP2A-peptides significantly elicit LMP2A-specific IFN-γ-producing cells and rousted cytotoxic T lymphocytes (CTLs)in vitroandin vivo. In addition, LMP2A-specific immune responses induced by the reconstituted complexes of MtHsp70 and LMP2A-peptides mediated potently protective activity as well as therapeutic efficacy against LMP2A-expressed tumor challenge in mouse models. These studies provide new insights for the development of novel LMP2A-based vaccines against EBV-associated malignancies.
Epstein–Barr virus (EBV) latent membrane protein 2A (LMP2A) is a subdominant antigen expressed in EBV-associated malignancies, such as Hodgkin's diseases (HD) and nasopharyngeal carcinoma. A large number of previous studies have described LMP2A as an ideal target antigen in immunotherapy of EBV-related diseases, while limited successes have been achieved in clinical trials. Mycobacterium tuberculosis heat shock protein 70 (MtHsp70) is known as an effective molecular adjuvant for protein- or epitope-based vaccines. In the present study, we reconstituted two chaperone complexes of MtHsp70 and LMP2A-derived peptides (LMP2A356–364 FLYALALLL and LMP2A426–434 CLGGLLTMV) in vitro. We then investigated LMP2A-specific immune responses induced by reconstituted complexes of MtHsp70 and LMP2A-peptides using both EBV infected healthy donor PBMCs and HLA-A2.1 transgenic mouse models. We found that reconstituted complexes of MtHsp70 and LMP2A-peptides significantly elicit LMP2A-specific IFN-γ-producing cells and rousted cytotoxic T lymphocytes (CTLs) in vitro and in vivo. In addition, LMP2A-specific immune responses induced by the reconstituted complexes of MtHsp70 and LMP2A-peptides mediated potently protective activity as well as therapeutic efficacy against LMP2A-expressed tumor challenge in mouse models. These studies provide new insights for the development of novel LMP2A-based vaccines against EBV-associated malignancies.
Epstein–Barr virus (EBV) latent membrane protein 2A (LMP2A) is a subdominant antigen expressed in EBV-associated malignancies, such as Hodgkin's diseases (HD) and nasopharyngeal carcinoma. A large number of previous studies have described LMP2A as an ideal target antigen in immunotherapy of EBV-related diseases, while limited successes have been achieved in clinical trials. Mycobacterium tuberculosis heat shock protein 70 (MtHsp70) is known as an effective molecular adjuvant for protein- or epitope-based vaccines. In the present study, we reconstituted two chaperone complexes of MtHsp70 and LMP2A-derived peptides (LMP2A₃₅₆–₃₆₄ FLYALALLL and LMP2A₄₂₆–₄₃₄ CLGGLLTMV) in vitro. We then investigated LMP2A-specific immune responses induced by reconstituted complexes of MtHsp70 and LMP2A-peptides using both EBV infected healthy donor PBMCs and HLA-A2.1 transgenic mouse models. We found that reconstituted complexes of MtHsp70 and LMP2A-peptides significantly elicit LMP2A-specific IFN-γ-producing cells and rousted cytotoxic T lymphocytes (CTLs) in vitro and in vivo. In addition, LMP2A-specific immune responses induced by the reconstituted complexes of MtHsp70 and LMP2A-peptides mediated potently protective activity as well as therapeutic efficacy against LMP2A-expressed tumor challenge in mouse models. These studies provide new insights for the development of novel LMP2A-based vaccines against EBV-associated malignancies.
Epstein-Barr virus (EBV) latent membrane protein 2A (LMP2A) is a subdominant antigen expressed in EBV-associated malignancies, such as Hodgkin's diseases (HD) and nasopharyngeal carcinoma. A large number of previous studies have described LMP2A as an ideal target antigen in immunotherapy of EBV-related diseases, while limited successes have been achieved in clinical trials. Mycobacterium tuberculosis heat shock protein 70 (MtHsp70) is known as an effective molecular adjuvant for protein- or epitope-based vaccines. In the present study, we reconstituted two chaperone complexes of MtHsp70 and LMP2A-derived peptides (LMP2A sub(356-364 FLYALALLL and LMP2A) sub(4)26-434 CLGGLLTMV) in vitro. We then investigated LMP2A-specific immune responses induced by reconstituted complexes of MtHsp70 and LMP2A-peptides using both EBV infected healthy donor PBMCs and HLA-A2.1 transgenic mouse models. We found that reconstituted complexes of MtHsp70 and LMP2A-peptides significantly elicit LMP2A-specific IFN-[gamma]-producing cells and rousted cytotoxic T lymphocytes (CTLs) in vitro and in vivo. In addition, LMP2A-specific immune responses induced by the reconstituted complexes of MtHsp70 and LMP2A-peptides mediated potently protective activity as well as therapeutic efficacy against LMP2A-expressed tumor challenge in mouse models. These studies provide new insights for the development of novel LMP2A-based vaccines against EBV-associated malignancies.
Abstract Epstein–Barr virus (EBV) latent membrane protein 2A (LMP2A) is a subdominant antigen expressed in EBV-associated malignancies, such as Hodgkin's diseases (HD) and nasopharyngeal carcinoma. A large number of previous studies have described LMP2A as an ideal target antigen in immunotherapy of EBV-related diseases, while limited successes have been achieved in clinical trials. Mycobacterium tuberculosis heat shock protein 70 (MtHsp70) is known as an effective molecular adjuvant for protein- or epitope-based vaccines. In the present study, we reconstituted two chaperone complexes of MtHsp70 and LMP2A-derived peptides (LMP2A356–364 FLYALALLL and LMP2A426–434 CLGGLLTMV) in vitro . We then investigated LMP2A-specific immune responses induced by reconstituted complexes of MtHsp70 and LMP2A-peptides using both EBV infected healthy donor PBMCs and HLA-A2.1 transgenic mouse models. We found that reconstituted complexes of MtHsp70 and LMP2A-peptides significantly elicit LMP2A-specific IFN-γ-producing cells and rousted cytotoxic T lymphocytes (CTLs) in vitro and in vivo . In addition, LMP2A-specific immune responses induced by the reconstituted complexes of MtHsp70 and LMP2A-peptides mediated potently protective activity as well as therapeutic efficacy against LMP2A-expressed tumor challenge in mouse models. These studies provide new insights for the development of novel LMP2A-based vaccines against EBV-associated malignancies.
Author Liu, Genyan
Yao, Kun
Zhou, Feng
Li, Linyun
Peng, Guangyong
Wang, Bing
Chen, Yun
Chi, Jing
Author_xml – sequence: 1
  fullname: Liu, Genyan
– sequence: 2
  fullname: Yao, Kun
– sequence: 3
  fullname: Wang, Bing
– sequence: 4
  fullname: Zhou, Feng
– sequence: 5
  fullname: Chen, Yun
– sequence: 6
  fullname: Li, Linyun
– sequence: 7
  fullname: Chi, Jing
– sequence: 8
  fullname: Peng, Guangyong
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24686689$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/21807054$$D View this record in MEDLINE/PubMed
BookMark eNqNks1u1DAUhSNURKeFRwAiIcQqw7WdH2dTVKpCkQZRMS3qzvI41-AhiYPtjDovw7PiaKZU6gZW_vvO8b0-PkoOettjkjwnMCdAyrfr-UYqZXqcUyBkDtUcSvYomRFesYwWhB8kM6BlnuUEbg6TI-_XAFAwUj9JDinhUEGRz5LfX1HZ3gcTxoBNqmw3tHiLPrU67bbKrqQK6Ixs04vlZQWp7Jv0_P23dPH5kp5mTTzaRNmAQzBNVGFrlAl368wPqIw2KlXbYIO9jbOrtN12ww8bdzB16Id4exROvrIPJgtjZ11qum7sTdg-TR5r2Xp8th-Pk-sP51dnF9niy8dPZ6eLTBWMhUwjkJysgFNeEsoL5KWqgBGqWMM15gwZSMbjhtYay5pIWWOtqa4KCTTX7Dh5s_MdnP01og-iM15h28oe7egFr2vCOC3r_yBLVheEVZF89YBc29H1sQ1B8ppDXeUwUcWOUs5671CLwZlOuq0gIKakxVrskxZT0gIqEZOOuhd793HVYfNXdRdtBF7vAemVbLWTvTL-nstLXpZ8aujljtPSCvndReZ6GW8qIL4pJXURiXc7AmMCG4NOeGWwV9gYhyqIxpp_FnvywEG1pjexrJ-4RX__LsJTAWI5fdzp35LoSYDfsD_td-qU
CODEN VACCDE
CitedBy_id crossref_primary_10_3390_vaccines9111290
crossref_primary_10_1080_21645515_2019_1670593
crossref_primary_10_1007_s10695_012_9724_z
crossref_primary_10_3389_fcimb_2018_00095
crossref_primary_10_1186_1479_5876_10_96
crossref_primary_10_3389_fonc_2024_1388999
crossref_primary_10_3389_fimmu_2021_677027
Cites_doi 10.1093/jac/dkg306
10.1016/j.tibs.2006.01.006
10.1182/blood-2004-07-2975
10.1200/JCO.2005.02.6195
10.1146/annurev.immunol.15.1.405
10.1128/JVI.80.2.883-890.2006
10.1016/S0140-6736(02)09672-1
10.1097/00002371-200407000-00008
10.1038/cmi.2008.45
10.1084/jem.186.8.1315
10.1084/jem.191.2.403
10.1016/S0002-9440(10)61130-3
10.4049/jimmunol.165.1.573
10.1128/JVI.01409-07
10.1038/nrd2224
10.1182/blood-2007-05-091280
10.2174/156652407780831575
10.1128/JVI.77.4.2757-2761.2003
10.1074/jbc.M704129200
10.4049/jimmunol.158.7.3325
10.1182/blood-2003-08-2828
10.1016/S0140-6736(05)66698-6
10.1016/j.anl.2006.05.019
10.1002/ijc.10309
10.1002/path.1569
10.1038/cmi.2009.13
10.1016/j.vaccine.2008.06.092
10.1128/JVI.67.12.7428-7435.1993
10.1126/science.278.5335.117
10.1128/JVI.78.2.768-778.2004
10.1038/cmi.2009.54
10.1200/JCO.2007.11.9941
10.1128/CVI.00029-07
10.1128/JVI.73.1.334-342.1999
10.1016/S0140-6736(95)91150-2
10.1016/S1471-4906(01)01896-8
10.1016/S0264-410X(01)00085-8
10.4049/jimmunol.180.5.3122
10.1016/j.addr.2005.01.002
10.1182/blood.V92.7.2477
10.1517/14712590802614538
10.1128/JVI.70.8.5357-5362.1996
ContentType Journal Article
Copyright Elsevier Ltd
2011 Elsevier Ltd
2015 INIST-CNRS
Copyright © 2011 Elsevier Ltd. All rights reserved.
Copyright Elsevier Limited Oct 6, 2011
Copyright_xml – notice: Elsevier Ltd
– notice: 2011 Elsevier Ltd
– notice: 2015 INIST-CNRS
– notice: Copyright © 2011 Elsevier Ltd. All rights reserved.
– notice: Copyright Elsevier Limited Oct 6, 2011
DBID FBQ
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
3V.
7QL
7RV
7T2
7T5
7U9
7X7
7XB
88C
88E
8AO
8C1
8FE
8FH
8FI
8FJ
8FK
8G5
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
C1K
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
GUQSH
H94
HCIFZ
K9-
K9.
KB0
LK8
M0R
M0S
M0T
M1P
M2O
M7N
M7P
MBDVC
NAPCQ
PQEST
PQQKQ
PQUKI
Q9U
7X8
DOI 10.1016/j.vaccine.2011.07.063
DatabaseName AGRIS
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
ProQuest Central (Corporate)
Bacteriology Abstracts (Microbiology B)
ProQuest Nursing and Allied Health Journals
Health and Safety Science Abstracts (Full archive)
Immunology Abstracts
Virology and AIDS Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Healthcare Administration Database (Alumni)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Public Health Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
Research Library (Alumni Edition)
ProQuest Central (Alumni Edition)
ProQuest Central
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
Environmental Sciences and Pollution Management
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
Research Library Prep
AIDS and Cancer Research Abstracts
SciTech Premium Collection
Consumer Health Database (Alumni Edition)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Consumer Health Database
Health & Medical Collection (Alumni Edition)
Healthcare Administration Database
Medical Database
Research Library
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biological Science Database
Research Library (Corporate)
Nursing & Allied Health Premium
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central Basic
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Research Library Prep
ProQuest Central Student
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
Research Library (Alumni Edition)
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Family Health (Alumni Edition)
Environmental Sciences and Pollution Management
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biological Science Collection
AIDS and Cancer Research Abstracts
ProQuest Research Library
Health & Safety Science Abstracts
ProQuest Medical Library (Alumni)
ProQuest Public Health
Virology and AIDS Abstracts
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Family Health
ProQuest One Academic Eastern Edition
ProQuest Health Management
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest Health Management (Alumni Edition)
Immunology Abstracts
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Research Library Prep


AIDS and Cancer Research Abstracts

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
– sequence: 4
  dbid: FBQ
  name: AGRIS
  url: http://www.fao.org/agris/Centre.asp?Menu_1ID=DB&Menu_2ID=DB1&Language=EN&Content=http://www.fao.org/agris/search?Language=EN
  sourceTypes: Publisher
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Veterinary Medicine
Biology
Pharmacy, Therapeutics, & Pharmacology
EISSN 1873-2518
EndPage 7423
ExternalDocumentID 3218552921
10_1016_j_vaccine_2011_07_063
21807054
24686689
US201500142195
S0264410X1101108X
1_s2_0_S0264410X1101108X
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
--K
--M
.1-
.FO
.GJ
.~1
0R~
0SF
123
1B1
1P~
1RT
1~.
1~5
29Q
3V.
4.4
457
4G.
53G
5RE
5VS
7-5
71M
7RV
7X7
88E
8AO
8C1
8FE
8FH
8FI
8FJ
8G5
8P~
9JM
AAAJQ
AABNK
AACTN
AAEDT
AAEDW
AAHBH
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AARKO
AAXKI
AAXUO
ABBQC
ABFNM
ABFRF
ABJNI
ABKYH
ABMAC
ABMZM
ABRWV
ABUWG
ABXDB
ACDAQ
ACGFO
ACGFS
ACIUM
ACPRK
ACRLP
ADBBV
ADEZE
ADFRT
ADMUD
ADVLN
AEBSH
AEFWE
AEKER
AENEX
AEVXI
AEXOQ
AFCTW
AFJKZ
AFKRA
AFKWA
AFRAH
AFRHN
AFTJW
AFXIZ
AGEKW
AGGSO
AGHFR
AGUBO
AGYEJ
AHHHB
AHMBA
AIEXJ
AIKHN
AITUG
AJOXV
AJRQY
AJUYK
AKRWK
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
ANZVX
AQUVI
ASPBG
AVWKF
AXJTR
AZFZN
AZQEC
BBNVY
BENPR
BHPHI
BKEYQ
BKNYI
BKOJK
BLXMC
BNPGV
BPHCQ
BVXVI
CCPQU
CJTIS
CNWQP
CS3
DWQXO
EBS
EFJIC
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
FYUFA
G-2
G-Q
GBLVA
GNUQQ
GUQSH
HCIFZ
HEJ
HLV
HMG
HMK
HMO
HVGLF
HX~
HZ~
IHE
J1W
K9-
KOM
L7B
LK8
LUGTX
LW9
M0R
M0T
M1P
M29
M2O
M41
M7P
MO0
N9A
NAPCQ
O-L
O9-
O9~
OAUVE
OK0
OZT
P-8
P-9
P2P
PC.
PQQKQ
PROAC
PSQYO
Q38
R2-
RIG
ROL
RPZ
SAB
SAE
SCC
SDF
SDG
SDP
SES
SEW
SIN
SNL
SPCBC
SSH
SSI
SSZ
SVS
T5K
UV1
WH7
WOW
WUQ
XPP
Z5R
ZGI
ZXP
~G-
AAIAV
ABLVK
ABYKQ
AESVU
AJBFU
EFLBG
HMCUK
LCYCR
QYZTP
UKHRP
ABPIF
ABPTK
FBQ
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QL
7T2
7T5
7U9
7XB
8FK
C1K
H94
K9.
M7N
MBDVC
PQEST
PQUKI
Q9U
7X8
ID FETCH-LOGICAL-c533t-fe0141b082861285e86c70312c3d8fe43e30a38312fffe691aa9e9f2f75a024f3
IEDL.DBID 8C1
ISSN 0264-410X
IngestDate Thu Oct 24 23:07:59 EDT 2024
Fri Oct 25 05:21:53 EDT 2024
Thu Oct 10 21:02:53 EDT 2024
Thu Sep 26 16:15:36 EDT 2024
Sat Sep 28 08:34:05 EDT 2024
Sun Oct 22 16:08:31 EDT 2023
Wed Dec 27 19:02:04 EST 2023
Fri Feb 23 02:31:55 EST 2024
Tue Oct 15 22:55:51 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 43
Keywords Heat shock protein 70
Adjuvant
Latent membrane protein 2A
Immunotherapy
Epstein–Barr virus
Gammaherpesvirinae
Mycobacterium
Membrane protein
Peptides
Herpesviridae
Cytotoxicity
Epstein Barr virus
Malignant tumor
Virus
Mycobacteriales
Immunological adjuvant
T-Lymphocyte
Heat shock protein
Mycobacteriaceae
Bacteria
Actinomycetes
Epstein-Barr virus
Cytotoxic T lymphocyte
Cancer
Language English
License CC BY 4.0
Copyright © 2011 Elsevier Ltd. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c533t-fe0141b082861285e86c70312c3d8fe43e30a38312fffe691aa9e9f2f75a024f3
Notes http://dx.doi.org/10.1016/j.vaccine.2011.07.063
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
PMID 21807054
PQID 1498097407
PQPubID 105530
PageCount 10
ParticipantIDs proquest_miscellaneous_899138269
proquest_miscellaneous_896395137
proquest_journals_1498097407
crossref_primary_10_1016_j_vaccine_2011_07_063
pubmed_primary_21807054
pascalfrancis_primary_24686689
fao_agris_US201500142195
elsevier_sciencedirect_doi_10_1016_j_vaccine_2011_07_063
elsevier_clinicalkeyesjournals_1_s2_0_S0264410X1101108X
PublicationCentury 2000
PublicationDate 2011-10-06
PublicationDateYYYYMMDD 2011-10-06
PublicationDate_xml – month: 10
  year: 2011
  text: 2011-10-06
  day: 06
PublicationDecade 2010
PublicationPlace Kidlington
PublicationPlace_xml – name: Kidlington
– name: Netherlands
PublicationTitle Vaccine
PublicationTitleAlternate Vaccine
PublicationYear 2011
Publisher Elsevier Ltd
Elsevier
Elsevier Limited
Publisher_xml – name: Elsevier Ltd
– name: Elsevier
– name: Elsevier Limited
References Taylor, Haigh, Gudgeon, Phelps, Lee, Steven (bib0110) 2004; 78
Haque, Wilkie, Taylor, Amlot, Murad, Iley (bib0010) 2002; 360
Blachere, Li, Chandawarkar, Suto, Jaikaria, Basu (bib0155) 1997; 186
Bollard, Gottschalk, Leen, Weiss, Straathof, Carrum (bib0140) 2007; 110
Rickinson, Moss (bib0050) 1997; 15
Straathof, Bollard, Popat, Huls, Lopez, Morriss (bib0090) 2005; 105
Cancer IAfRo (bib0005) 1997; 70
Wang, Yao, Liu, Xie, Zhou, Chen (bib0055) 2009; 6
Bollard, Straathof, Huls, Leen, Lacuesta, Davis (bib0040) 2004; 27
Lautscham, Haigh, Mayrhofer, Taylor, Croom-Carter, Leese (bib0070) 2003; 77
Grange, Bottasso, Stanford, Stanford (bib0195) 2008; 26
Testori, Richards, Whitman, Mann, Lutzky, Camacho (bib0205) 2008; 26
Bendz, Ruhland, Pandya, Hainzl, Riegelsberger, Brauchle (bib0160) 2007; 282
Liu, Wu, Rowse, Emtage (bib0120) 2007; 14
Lee, Thomas, Murray, Khanim, Kaur, Young (bib0060) 1993; 67
Wan, Zhou, Chen, An, Chen, Zhang (bib0165) 2004; 103
Heussinger, Buttner, Ott, Brachtel, Pilch, Kremmer (bib0025) 2004; 203
Bharadwaj, Sherritt, Khanna, Moss (bib0095) 2001; 19
Elliott, Suhrbier, Miles, Lawrence, Pye, Le (bib0175) 2008; 82
Huang, Richmond, Suzue, Eisen, Young (bib0125) 2000; 191
Calderwood, Khaleque, Sawyer, Ciocca (bib0215) 2006; 31
Murray, Constandinou, Crocker, Young, Ambinder (bib0150) 1998; 92
Lin, Lo, Lee, Ren, Hwang, Cheng (bib0100) 2002; 62
Wong, Bos, Sherman (bib0190) 2008; 180
Sun, Yao, Chen, Zhou (bib0035) 2004; 117
Purcell, McCluskey, Rossjohn (bib0105) 2007; 6
Comoli, Pedrazzoli, Maccario, Basso, Carminati, Labirio (bib0145) 2005; 23
Wang (bib0180) 2001; 22
Ito, Kondo, Demachi-Okamura, Akatsuka, Tsujimura, Tanimoto (bib0220) 2006; 80
Meij, Leen, Rickinson, Verkoeijen, Vervoort, Bloemena (bib0085) 2002; 99
Walker, Keeble, Colaco (bib0115) 2007; 7
Xu, Yao, Yu, Chen, Lu, Sun (bib0030) 2006; 33
Lee, Chan, Cheung, Thomas, CroomCarter, Dawson (bib0065) 2000; 165
Redchenko, Rickinson (bib0135) 1999; 73
Mittendorf, Holmes, Murray, von Hofe, Peoples (bib0185) 2009; 9
Tamura, Peng, Liu, Daou, Srivastava (bib0200) 1997; 278
Rooney, Smith, Ng, Loftin, Li, Krance (bib0015) 1995; 345
Liu, Yao, Wang, Chen, Zhou, Guo (bib0130) 2009; 6
Lee, Tierney, Thomas, Brooks, Rickinson (bib0075) 1997; 158
Khanna, Burrows, Moss, Silins (bib0080) 1996; 70
Rolland (bib0170) 2005; 57
Tao, Yang, Huang, Swinnen, Ambinder (bib0225) 2002; 160
Chen, Yao, Wang, Qing, Liu (bib0020) 2008; 5
Swanson-Mungerson, Ikeda, Lev, Longnecker, Portis (bib0045) 2003; 52
Wei, Sham (bib0210) 2005; 365
Rooney (10.1016/j.vaccine.2011.07.063_bib0015) 1995; 345
Testori (10.1016/j.vaccine.2011.07.063_bib0205) 2008; 26
Swanson-Mungerson (10.1016/j.vaccine.2011.07.063_bib0045) 2003; 52
Wan (10.1016/j.vaccine.2011.07.063_bib0165) 2004; 103
Mittendorf (10.1016/j.vaccine.2011.07.063_bib0185) 2009; 9
Bharadwaj (10.1016/j.vaccine.2011.07.063_bib0095) 2001; 19
Huang (10.1016/j.vaccine.2011.07.063_bib0125) 2000; 191
Liu (10.1016/j.vaccine.2011.07.063_bib0120) 2007; 14
Heussinger (10.1016/j.vaccine.2011.07.063_bib0025) 2004; 203
Lee (10.1016/j.vaccine.2011.07.063_bib0075) 1997; 158
Xu (10.1016/j.vaccine.2011.07.063_bib0030) 2006; 33
Taylor (10.1016/j.vaccine.2011.07.063_bib0110) 2004; 78
Bendz (10.1016/j.vaccine.2011.07.063_bib0160) 2007; 282
Khanna (10.1016/j.vaccine.2011.07.063_bib0080) 1996; 70
Cancer IAfRo (10.1016/j.vaccine.2011.07.063_bib0005) 1997; 70
Lee (10.1016/j.vaccine.2011.07.063_bib0065) 2000; 165
Liu (10.1016/j.vaccine.2011.07.063_bib0130) 2009; 6
Haque (10.1016/j.vaccine.2011.07.063_bib0010) 2002; 360
Lee (10.1016/j.vaccine.2011.07.063_bib0060) 1993; 67
Elliott (10.1016/j.vaccine.2011.07.063_bib0175) 2008; 82
Ito (10.1016/j.vaccine.2011.07.063_bib0220) 2006; 80
Wang (10.1016/j.vaccine.2011.07.063_bib0055) 2009; 6
Purcell (10.1016/j.vaccine.2011.07.063_bib0105) 2007; 6
Grange (10.1016/j.vaccine.2011.07.063_bib0195) 2008; 26
Tao (10.1016/j.vaccine.2011.07.063_bib0225) 2002; 160
Tamura (10.1016/j.vaccine.2011.07.063_bib0200) 1997; 278
Bollard (10.1016/j.vaccine.2011.07.063_bib0140) 2007; 110
Murray (10.1016/j.vaccine.2011.07.063_bib0150) 1998; 92
Walker (10.1016/j.vaccine.2011.07.063_bib0115) 2007; 7
Calderwood (10.1016/j.vaccine.2011.07.063_bib0215) 2006; 31
Wei (10.1016/j.vaccine.2011.07.063_bib0210) 2005; 365
Lin (10.1016/j.vaccine.2011.07.063_bib0100) 2002; 62
Rolland (10.1016/j.vaccine.2011.07.063_bib0170) 2005; 57
Wang (10.1016/j.vaccine.2011.07.063_bib0180) 2001; 22
Sun (10.1016/j.vaccine.2011.07.063_bib0035) 2004; 117
Straathof (10.1016/j.vaccine.2011.07.063_bib0090) 2005; 105
Lautscham (10.1016/j.vaccine.2011.07.063_bib0070) 2003; 77
Blachere (10.1016/j.vaccine.2011.07.063_bib0155) 1997; 186
Redchenko (10.1016/j.vaccine.2011.07.063_bib0135) 1999; 73
Meij (10.1016/j.vaccine.2011.07.063_bib0085) 2002; 99
Comoli (10.1016/j.vaccine.2011.07.063_bib0145) 2005; 23
Bollard (10.1016/j.vaccine.2011.07.063_bib0040) 2004; 27
Rickinson (10.1016/j.vaccine.2011.07.063_bib0050) 1997; 15
Chen (10.1016/j.vaccine.2011.07.063_bib0020) 2008; 5
Wong (10.1016/j.vaccine.2011.07.063_bib0190) 2008; 180
References_xml – volume: 6
  start-page: 404
  year: 2007
  end-page: 414
  ident: bib0105
  article-title: More than one reason to rethink the use of peptides in vaccine design
  publication-title: Nat Rev Drug Discov
  contributor:
    fullname: Rossjohn
– volume: 180
  start-page: 3122
  year: 2008
  end-page: 3131
  ident: bib0190
  article-title: Tumor-Specific CD4
  publication-title: J Immunol
  contributor:
    fullname: Sherman
– volume: 33
  start-page: 441
  year: 2006
  end-page: 446
  ident: bib0030
  article-title: Anti-tumor immunity against nasopharyngeal carcinoma by means of LMP2A-specific cytotoxic T lymphocytes induced by dendritic cells
  publication-title: Auris Nasus Larynx
  contributor:
    fullname: Sun
– volume: 62
  start-page: 6952
  year: 2002
  end-page: 6958
  ident: bib0100
  article-title: Immunization with Epstein–Barr virus (EBV) peptide-pulsed dendritic cells induces functional CD8+T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma
  publication-title: Cancer Res
  contributor:
    fullname: Cheng
– volume: 57
  start-page: 669
  year: 2005
  end-page: 673
  ident: bib0170
  article-title: Gene medicines: the end of the beginning?
  publication-title: Adv Drug Delivery Rev
  contributor:
    fullname: Rolland
– volume: 70
  start-page: 5357
  year: 1996
  end-page: 5362
  ident: bib0080
  article-title: Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein–Barr virus (EBV) latent membrane protein 2A: implications for cytotoxic T-lymphocyte control of EBV-associated malignancies
  publication-title: J Virol
  contributor:
    fullname: Silins
– volume: 67
  start-page: 7428
  year: 1993
  end-page: 7435
  ident: bib0060
  article-title: HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein–Barr virus isolates through a defined epitope in latent membrane protein LMP2
  publication-title: J Virol
  contributor:
    fullname: Young
– volume: 19
  start-page: 3769
  year: 2001
  end-page: 3777
  ident: bib0095
  article-title: Contrasting Epstein–Barr virus-specific cytotoxic T cell responses to HLA A2-restricted epitopes in humans and HLA transgenic mice: implications for vaccine design
  publication-title: Vaccine
  contributor:
    fullname: Moss
– volume: 27
  start-page: 317
  year: 2004
  end-page: 327
  ident: bib0040
  article-title: The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease
  publication-title: J Immunother
  contributor:
    fullname: Davis
– volume: 70
  start-page: 1
  year: 1997
  end-page: 492
  ident: bib0005
  publication-title: Proceedings of the IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Epstein–Barr Virus and Kaposi's Sarcoma Herpesvirus/Human Herpesvirus 8
  contributor:
    fullname: Cancer IAfRo
– volume: 23
  start-page: 8942
  year: 2005
  end-page: 8949
  ident: bib0145
  article-title: Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein–Barr virus-targeted cytotoxic T lymphocytes
  publication-title: J Clin Oncol
  contributor:
    fullname: Labirio
– volume: 360
  start-page: 436
  year: 2002
  end-page: 442
  ident: bib0010
  article-title: Treatment of Epstein–Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells
  publication-title: Lancet
  contributor:
    fullname: Iley
– volume: 92
  start-page: 2477
  year: 1998
  end-page: 2483
  ident: bib0150
  article-title: Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein–Barr virus-positive Hodgkin's disease
  publication-title: Blood
  contributor:
    fullname: Ambinder
– volume: 14
  start-page: 1013
  year: 2007
  end-page: 1023
  ident: bib0120
  article-title: Induction of CD4-independent E7-specific CD8
  publication-title: Clin Vaccine Immunol
  contributor:
    fullname: Emtage
– volume: 77
  start-page: 2757
  year: 2003
  end-page: 2761
  ident: bib0070
  article-title: Identification of a TAP-independent, immunoproteasome-dependent CD8
  publication-title: J Virol
  contributor:
    fullname: Leese
– volume: 110
  start-page: 2838
  year: 2007
  end-page: 2845
  ident: bib0140
  article-title: Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer
  publication-title: Blood
  contributor:
    fullname: Carrum
– volume: 26
  start-page: 955
  year: 2008
  end-page: 962
  ident: bib0205
  article-title: Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine
  publication-title: J Clin Oncol
  contributor:
    fullname: Camacho
– volume: 52
  start-page: 152
  year: 2003
  end-page: 154
  ident: bib0045
  article-title: Identification of latent membrane protein 2A (LMP2A) specific targets for treatment and eradication of Epstein–Barr virus (EBV)-associated diseases
  publication-title: J Antimicrob Chemother
  contributor:
    fullname: Portis
– volume: 278
  start-page: 117
  year: 1997
  end-page: 120
  ident: bib0200
  article-title: Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations
  publication-title: Science
  contributor:
    fullname: Srivastava
– volume: 26
  start-page: 4984
  year: 2008
  end-page: 4990
  ident: bib0195
  article-title: The use of mycobacterial adjuvant-based agents for immunotherapy of cancer
  publication-title: Vaccine
  contributor:
    fullname: Stanford
– volume: 117
  start-page: 1558
  year: 2004
  end-page: 1563
  ident: bib0035
  article-title: Induction of T-cell immunity against Epstein–Barr virus-associated tumors by means of adenovirally transduced dendritic cells
  publication-title: Chin Med J
  contributor:
    fullname: Zhou
– volume: 31
  start-page: 164
  year: 2006
  end-page: 172
  ident: bib0215
  article-title: Heat shock proteins in cancer: chaperones of tumorigenesis
  publication-title: Trends Biochem Sci
  contributor:
    fullname: Ciocca
– volume: 5
  start-page: 365
  year: 2008
  end-page: 372
  ident: bib0020
  article-title: Potent dendritic cell vaccine loaded with latent membrane protein 2A (LMP2A)
  publication-title: Cell Mol Immunol
  contributor:
    fullname: Liu
– volume: 73
  start-page: 334
  year: 1999
  end-page: 342
  ident: bib0135
  article-title: Accessing Epstein–Barr virus-specific T-cell memory with peptide-loaded dendritic cells
  publication-title: J Virol
  contributor:
    fullname: Rickinson
– volume: 186
  start-page: 1315
  year: 1997
  end-page: 1322
  ident: bib0155
  article-title: Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity
  publication-title: J Exp Med
  contributor:
    fullname: Basu
– volume: 103
  start-page: 1747
  year: 2004
  end-page: 1754
  ident: bib0165
  article-title: Novel heat shock protein Hsp70L1 activates dendritic cells and acts as a Th1 polarizing adjuvant
  publication-title: Blood
  contributor:
    fullname: Zhang
– volume: 78
  start-page: 768
  year: 2004
  end-page: 778
  ident: bib0110
  article-title: Dual stimulation of Epstein–Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma
  publication-title: J Virol
  contributor:
    fullname: Steven
– volume: 282
  start-page: 31688
  year: 2007
  end-page: 31702
  ident: bib0160
  article-title: Human heat shock protein 70 enhances tumor antigen presentation through complex formation and intracellular antigen delivery without innate immune signaling
  publication-title: J Biol Chem
  contributor:
    fullname: Brauchle
– volume: 365
  start-page: 2041
  year: 2005
  end-page: 2054
  ident: bib0210
  article-title: Nasopharyngeal carcinoma
  publication-title: Lancet
  contributor:
    fullname: Sham
– volume: 15
  start-page: 405
  year: 1997
  end-page: 431
  ident: bib0050
  article-title: Human cytotoxic T lymphocyte responses to Epstein–Barr virus infection
  publication-title: Annu Rev Immunol
  contributor:
    fullname: Moss
– volume: 82
  start-page: 1448
  year: 2008
  end-page: 1457
  ident: bib0175
  article-title: Phase I trial of a CD8
  publication-title: J Virol
  contributor:
    fullname: Le
– volume: 160
  start-page: 1839
  year: 2002
  end-page: 1845
  ident: bib0225
  article-title: Conservation of Epstein–Barr virus cytotoxic T-cell epitopes in posttransplant lymphomas: implications for immune therapy
  publication-title: Am J Pathol
  contributor:
    fullname: Ambinder
– volume: 99
  start-page: 93
  year: 2002
  end-page: 99
  ident: bib0085
  article-title: Identification and prevalence of CD8(+) T-cell responses directed against Epstein–Barr virus-encoded latent membrane protein 1 and latent membrane protein 2
  publication-title: Int J Cancer
  contributor:
    fullname: Bloemena
– volume: 158
  start-page: 3325
  year: 1997
  end-page: 3334
  ident: bib0075
  article-title: Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy
  publication-title: J Immunol
  contributor:
    fullname: Rickinson
– volume: 7
  start-page: 339
  year: 2007
  end-page: 350
  ident: bib0115
  article-title: Mycobacterial heat shock proteins as vaccines—a model of facilitated antigen presentation
  publication-title: Curr Mol Med
  contributor:
    fullname: Colaco
– volume: 203
  start-page: 696
  year: 2004
  end-page: 699
  ident: bib0025
  article-title: Expression of the Epstein–Barr virus (EBV)-encoded latent membrane protein 2A (LMP2A) in EBV-associated nasopharyngeal carcinoma
  publication-title: J Pathol
  contributor:
    fullname: Kremmer
– volume: 9
  start-page: 71
  year: 2009
  end-page: 78
  ident: bib0185
  article-title: CD4
  publication-title: Expert Opin Biol Ther
  contributor:
    fullname: Peoples
– volume: 191
  start-page: 403
  year: 2000
  end-page: 408
  ident: bib0125
  article-title: In vivo cytotoxic T lymphocyte elicitation by mycobacterial heat shock protein 70 fusion proteins maps to a discrete domain and is CD4(+) T cell independent
  publication-title: J Exp Med
  contributor:
    fullname: Young
– volume: 6
  start-page: 423
  year: 2009
  end-page: 431
  ident: bib0130
  article-title: Immunotherapy of Epstein–Barr virus associated malignancies using mycobacterial HSP70 and LMP2A356-364 epitope fusion protein
  publication-title: Cell Mol Immunol
  contributor:
    fullname: Guo
– volume: 345
  start-page: 9
  year: 1995
  end-page: 13
  ident: bib0015
  article-title: Use of gene-modified virus-specific T lymphocytes to control Epstein–Barr-virus-related lymphoproliferation
  publication-title: Lancet
  contributor:
    fullname: Krance
– volume: 165
  start-page: 573
  year: 2000
  end-page: 582
  ident: bib0065
  article-title: CTL control of EBV in nasopharyngeal carcinoma (NPC): EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of the tumor cells
  publication-title: J Immunol
  contributor:
    fullname: Dawson
– volume: 22
  start-page: 269
  year: 2001
  end-page: 276
  ident: bib0180
  article-title: The role of MHC class II-restricted tumor antigens and CD4
  publication-title: Trends Immunol
  contributor:
    fullname: Wang
– volume: 6
  start-page: 97
  year: 2009
  end-page: 103
  ident: bib0055
  article-title: Computational prediction and identification of Epstein–Barr virus latent membrane protein 2A antigen-specific CD8
  publication-title: Cell Mol Immunol
  contributor:
    fullname: Chen
– volume: 105
  start-page: 1898
  year: 2005
  end-page: 1904
  ident: bib0090
  article-title: Treatment of nasopharyngeal carcinoma with Epstein–Barr virus-specific T lymphocytes
  publication-title: Blood
  contributor:
    fullname: Morriss
– volume: 80
  start-page: 883
  year: 2006
  end-page: 890
  ident: bib0220
  article-title: Three immunoproteasome-associated subunits cooperatively generate a cytotoxic T-lymphocyte epitope of Epstein–Barr virus LMP2A by overcoming specific structures resistant to epitope liberation
  publication-title: J Virol
  contributor:
    fullname: Tanimoto
– volume: 52
  start-page: 152
  issue: August (2)
  year: 2003
  ident: 10.1016/j.vaccine.2011.07.063_bib0045
  article-title: Identification of latent membrane protein 2A (LMP2A) specific targets for treatment and eradication of Epstein–Barr virus (EBV)-associated diseases
  publication-title: J Antimicrob Chemother
  doi: 10.1093/jac/dkg306
  contributor:
    fullname: Swanson-Mungerson
– volume: 31
  start-page: 164
  issue: 3
  year: 2006
  ident: 10.1016/j.vaccine.2011.07.063_bib0215
  article-title: Heat shock proteins in cancer: chaperones of tumorigenesis
  publication-title: Trends Biochem Sci
  doi: 10.1016/j.tibs.2006.01.006
  contributor:
    fullname: Calderwood
– volume: 105
  start-page: 1898
  issue: March (5)
  year: 2005
  ident: 10.1016/j.vaccine.2011.07.063_bib0090
  article-title: Treatment of nasopharyngeal carcinoma with Epstein–Barr virus-specific T lymphocytes
  publication-title: Blood
  doi: 10.1182/blood-2004-07-2975
  contributor:
    fullname: Straathof
– volume: 23
  start-page: 8942
  issue: December (35)
  year: 2005
  ident: 10.1016/j.vaccine.2011.07.063_bib0145
  article-title: Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein–Barr virus-targeted cytotoxic T lymphocytes
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2005.02.6195
  contributor:
    fullname: Comoli
– volume: 117
  start-page: 1558
  issue: October (10)
  year: 2004
  ident: 10.1016/j.vaccine.2011.07.063_bib0035
  article-title: Induction of T-cell immunity against Epstein–Barr virus-associated tumors by means of adenovirally transduced dendritic cells
  publication-title: Chin Med J
  contributor:
    fullname: Sun
– volume: 15
  start-page: 405
  year: 1997
  ident: 10.1016/j.vaccine.2011.07.063_bib0050
  article-title: Human cytotoxic T lymphocyte responses to Epstein–Barr virus infection
  publication-title: Annu Rev Immunol
  doi: 10.1146/annurev.immunol.15.1.405
  contributor:
    fullname: Rickinson
– volume: 80
  start-page: 883
  issue: January (2)
  year: 2006
  ident: 10.1016/j.vaccine.2011.07.063_bib0220
  article-title: Three immunoproteasome-associated subunits cooperatively generate a cytotoxic T-lymphocyte epitope of Epstein–Barr virus LMP2A by overcoming specific structures resistant to epitope liberation
  publication-title: J Virol
  doi: 10.1128/JVI.80.2.883-890.2006
  contributor:
    fullname: Ito
– volume: 360
  start-page: 436
  issue: August (9331)
  year: 2002
  ident: 10.1016/j.vaccine.2011.07.063_bib0010
  article-title: Treatment of Epstein–Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells
  publication-title: Lancet
  doi: 10.1016/S0140-6736(02)09672-1
  contributor:
    fullname: Haque
– volume: 27
  start-page: 317
  issue: July–August (4)
  year: 2004
  ident: 10.1016/j.vaccine.2011.07.063_bib0040
  article-title: The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease
  publication-title: J Immunother
  doi: 10.1097/00002371-200407000-00008
  contributor:
    fullname: Bollard
– volume: 5
  start-page: 365
  issue: October (5)
  year: 2008
  ident: 10.1016/j.vaccine.2011.07.063_bib0020
  article-title: Potent dendritic cell vaccine loaded with latent membrane protein 2A (LMP2A)
  publication-title: Cell Mol Immunol
  doi: 10.1038/cmi.2008.45
  contributor:
    fullname: Chen
– volume: 186
  start-page: 1315
  issue: October (8)
  year: 1997
  ident: 10.1016/j.vaccine.2011.07.063_bib0155
  article-title: Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity
  publication-title: J Exp Med
  doi: 10.1084/jem.186.8.1315
  contributor:
    fullname: Blachere
– volume: 191
  start-page: 403
  issue: January (2)
  year: 2000
  ident: 10.1016/j.vaccine.2011.07.063_bib0125
  article-title: In vivo cytotoxic T lymphocyte elicitation by mycobacterial heat shock protein 70 fusion proteins maps to a discrete domain and is CD4(+) T cell independent
  publication-title: J Exp Med
  doi: 10.1084/jem.191.2.403
  contributor:
    fullname: Huang
– volume: 160
  start-page: 1839
  issue: May (5)
  year: 2002
  ident: 10.1016/j.vaccine.2011.07.063_bib0225
  article-title: Conservation of Epstein–Barr virus cytotoxic T-cell epitopes in posttransplant lymphomas: implications for immune therapy
  publication-title: Am J Pathol
  doi: 10.1016/S0002-9440(10)61130-3
  contributor:
    fullname: Tao
– volume: 165
  start-page: 573
  issue: July (1)
  year: 2000
  ident: 10.1016/j.vaccine.2011.07.063_bib0065
  article-title: CTL control of EBV in nasopharyngeal carcinoma (NPC): EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of the tumor cells
  publication-title: J Immunol
  doi: 10.4049/jimmunol.165.1.573
  contributor:
    fullname: Lee
– volume: 62
  start-page: 6952
  issue: December (23)
  year: 2002
  ident: 10.1016/j.vaccine.2011.07.063_bib0100
  article-title: Immunization with Epstein–Barr virus (EBV) peptide-pulsed dendritic cells induces functional CD8+T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma
  publication-title: Cancer Res
  contributor:
    fullname: Lin
– volume: 82
  start-page: 1448
  issue: February (3)
  year: 2008
  ident: 10.1016/j.vaccine.2011.07.063_bib0175
  article-title: Phase I trial of a CD8+T-cell peptide epitope-based vaccine for infectious mononucleosis
  publication-title: J Virol
  doi: 10.1128/JVI.01409-07
  contributor:
    fullname: Elliott
– volume: 6
  start-page: 404
  issue: May (5)
  year: 2007
  ident: 10.1016/j.vaccine.2011.07.063_bib0105
  article-title: More than one reason to rethink the use of peptides in vaccine design
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/nrd2224
  contributor:
    fullname: Purcell
– volume: 110
  start-page: 2838
  issue: October (8)
  year: 2007
  ident: 10.1016/j.vaccine.2011.07.063_bib0140
  article-title: Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer
  publication-title: Blood
  doi: 10.1182/blood-2007-05-091280
  contributor:
    fullname: Bollard
– volume: 7
  start-page: 339
  issue: June (4)
  year: 2007
  ident: 10.1016/j.vaccine.2011.07.063_bib0115
  article-title: Mycobacterial heat shock proteins as vaccines—a model of facilitated antigen presentation
  publication-title: Curr Mol Med
  doi: 10.2174/156652407780831575
  contributor:
    fullname: Walker
– volume: 77
  start-page: 2757
  issue: February (4)
  year: 2003
  ident: 10.1016/j.vaccine.2011.07.063_bib0070
  article-title: Identification of a TAP-independent, immunoproteasome-dependent CD8+T-cell epitope in Epstein–Barr virus latent membrane protein 2
  publication-title: J Virol
  doi: 10.1128/JVI.77.4.2757-2761.2003
  contributor:
    fullname: Lautscham
– volume: 282
  start-page: 31688
  issue: October (43)
  year: 2007
  ident: 10.1016/j.vaccine.2011.07.063_bib0160
  article-title: Human heat shock protein 70 enhances tumor antigen presentation through complex formation and intracellular antigen delivery without innate immune signaling
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M704129200
  contributor:
    fullname: Bendz
– volume: 158
  start-page: 3325
  issue: April (7)
  year: 1997
  ident: 10.1016/j.vaccine.2011.07.063_bib0075
  article-title: Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy
  publication-title: J Immunol
  doi: 10.4049/jimmunol.158.7.3325
  contributor:
    fullname: Lee
– volume: 103
  start-page: 1747
  issue: March (5)
  year: 2004
  ident: 10.1016/j.vaccine.2011.07.063_bib0165
  article-title: Novel heat shock protein Hsp70L1 activates dendritic cells and acts as a Th1 polarizing adjuvant
  publication-title: Blood
  doi: 10.1182/blood-2003-08-2828
  contributor:
    fullname: Wan
– volume: 365
  start-page: 2041
  issue: June (9476)
  year: 2005
  ident: 10.1016/j.vaccine.2011.07.063_bib0210
  article-title: Nasopharyngeal carcinoma
  publication-title: Lancet
  doi: 10.1016/S0140-6736(05)66698-6
  contributor:
    fullname: Wei
– volume: 33
  start-page: 441
  issue: December (4)
  year: 2006
  ident: 10.1016/j.vaccine.2011.07.063_bib0030
  article-title: Anti-tumor immunity against nasopharyngeal carcinoma by means of LMP2A-specific cytotoxic T lymphocytes induced by dendritic cells
  publication-title: Auris Nasus Larynx
  doi: 10.1016/j.anl.2006.05.019
  contributor:
    fullname: Xu
– volume: 99
  start-page: 93
  issue: May (1)
  year: 2002
  ident: 10.1016/j.vaccine.2011.07.063_bib0085
  article-title: Identification and prevalence of CD8(+) T-cell responses directed against Epstein–Barr virus-encoded latent membrane protein 1 and latent membrane protein 2
  publication-title: Int J Cancer
  doi: 10.1002/ijc.10309
  contributor:
    fullname: Meij
– volume: 203
  start-page: 696
  issue: June (2)
  year: 2004
  ident: 10.1016/j.vaccine.2011.07.063_bib0025
  article-title: Expression of the Epstein–Barr virus (EBV)-encoded latent membrane protein 2A (LMP2A) in EBV-associated nasopharyngeal carcinoma
  publication-title: J Pathol
  doi: 10.1002/path.1569
  contributor:
    fullname: Heussinger
– volume: 6
  start-page: 97
  issue: April (2)
  year: 2009
  ident: 10.1016/j.vaccine.2011.07.063_bib0055
  article-title: Computational prediction and identification of Epstein–Barr virus latent membrane protein 2A antigen-specific CD8+T-cell epitopes
  publication-title: Cell Mol Immunol
  doi: 10.1038/cmi.2009.13
  contributor:
    fullname: Wang
– volume: 26
  start-page: 4984
  issue: September (39)
  year: 2008
  ident: 10.1016/j.vaccine.2011.07.063_bib0195
  article-title: The use of mycobacterial adjuvant-based agents for immunotherapy of cancer
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2008.06.092
  contributor:
    fullname: Grange
– volume: 67
  start-page: 7428
  issue: December (12)
  year: 1993
  ident: 10.1016/j.vaccine.2011.07.063_bib0060
  article-title: HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein–Barr virus isolates through a defined epitope in latent membrane protein LMP2
  publication-title: J Virol
  doi: 10.1128/JVI.67.12.7428-7435.1993
  contributor:
    fullname: Lee
– volume: 278
  start-page: 117
  issue: October (5335)
  year: 1997
  ident: 10.1016/j.vaccine.2011.07.063_bib0200
  article-title: Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations
  publication-title: Science
  doi: 10.1126/science.278.5335.117
  contributor:
    fullname: Tamura
– volume: 78
  start-page: 768
  issue: January (2)
  year: 2004
  ident: 10.1016/j.vaccine.2011.07.063_bib0110
  article-title: Dual stimulation of Epstein–Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma
  publication-title: J Virol
  doi: 10.1128/JVI.78.2.768-778.2004
  contributor:
    fullname: Taylor
– volume: 6
  start-page: 423
  issue: December (6)
  year: 2009
  ident: 10.1016/j.vaccine.2011.07.063_bib0130
  article-title: Immunotherapy of Epstein–Barr virus associated malignancies using mycobacterial HSP70 and LMP2A356-364 epitope fusion protein
  publication-title: Cell Mol Immunol
  doi: 10.1038/cmi.2009.54
  contributor:
    fullname: Liu
– volume: 26
  start-page: 955
  issue: February (6)
  year: 2008
  ident: 10.1016/j.vaccine.2011.07.063_bib0205
  article-title: Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2007.11.9941
  contributor:
    fullname: Testori
– volume: 14
  start-page: 1013
  issue: August (8)
  year: 2007
  ident: 10.1016/j.vaccine.2011.07.063_bib0120
  article-title: Induction of CD4-independent E7-specific CD8+memory response by heat shock fusion protein
  publication-title: Clin Vaccine Immunol
  doi: 10.1128/CVI.00029-07
  contributor:
    fullname: Liu
– volume: 73
  start-page: 334
  issue: January (1)
  year: 1999
  ident: 10.1016/j.vaccine.2011.07.063_bib0135
  article-title: Accessing Epstein–Barr virus-specific T-cell memory with peptide-loaded dendritic cells
  publication-title: J Virol
  doi: 10.1128/JVI.73.1.334-342.1999
  contributor:
    fullname: Redchenko
– volume: 345
  start-page: 9
  issue: January (8941)
  year: 1995
  ident: 10.1016/j.vaccine.2011.07.063_bib0015
  article-title: Use of gene-modified virus-specific T lymphocytes to control Epstein–Barr-virus-related lymphoproliferation
  publication-title: Lancet
  doi: 10.1016/S0140-6736(95)91150-2
  contributor:
    fullname: Rooney
– volume: 22
  start-page: 269
  issue: May (5)
  year: 2001
  ident: 10.1016/j.vaccine.2011.07.063_bib0180
  article-title: The role of MHC class II-restricted tumor antigens and CD4+T cells in antitumor immunity
  publication-title: Trends Immunol
  doi: 10.1016/S1471-4906(01)01896-8
  contributor:
    fullname: Wang
– volume: 19
  start-page: 3769
  issue: 27
  year: 2001
  ident: 10.1016/j.vaccine.2011.07.063_bib0095
  article-title: Contrasting Epstein–Barr virus-specific cytotoxic T cell responses to HLA A2-restricted epitopes in humans and HLA transgenic mice: implications for vaccine design
  publication-title: Vaccine
  doi: 10.1016/S0264-410X(01)00085-8
  contributor:
    fullname: Bharadwaj
– volume: 180
  start-page: 3122
  issue: March (5)
  year: 2008
  ident: 10.1016/j.vaccine.2011.07.063_bib0190
  article-title: Tumor-Specific CD4+T cells render the tumor environment permissive for infiltration by low-avidity CD8+T cells
  publication-title: J Immunol
  doi: 10.4049/jimmunol.180.5.3122
  contributor:
    fullname: Wong
– volume: 57
  start-page: 669
  issue: 5
  year: 2005
  ident: 10.1016/j.vaccine.2011.07.063_bib0170
  article-title: Gene medicines: the end of the beginning?
  publication-title: Adv Drug Delivery Rev
  doi: 10.1016/j.addr.2005.01.002
  contributor:
    fullname: Rolland
– volume: 92
  start-page: 2477
  issue: October (7)
  year: 1998
  ident: 10.1016/j.vaccine.2011.07.063_bib0150
  article-title: Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein–Barr virus-positive Hodgkin's disease
  publication-title: Blood
  doi: 10.1182/blood.V92.7.2477
  contributor:
    fullname: Murray
– volume: 70
  start-page: 1
  year: 1997
  ident: 10.1016/j.vaccine.2011.07.063_bib0005
  publication-title: IARC Monogr Eval Carcinog Risks Hum
  contributor:
    fullname: Cancer IAfRo
– volume: 9
  start-page: 71
  issue: January (1)
  year: 2009
  ident: 10.1016/j.vaccine.2011.07.063_bib0185
  article-title: CD4+T cells in antitumor immunity: utility of an li-key HER2/neu hybrid peptide vaccine (AE37)
  publication-title: Expert Opin Biol Ther
  doi: 10.1517/14712590802614538
  contributor:
    fullname: Mittendorf
– volume: 70
  start-page: 5357
  issue: August (8)
  year: 1996
  ident: 10.1016/j.vaccine.2011.07.063_bib0080
  article-title: Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein–Barr virus (EBV) latent membrane protein 2A: implications for cytotoxic T-lymphocyte control of EBV-associated malignancies
  publication-title: J Virol
  doi: 10.1128/JVI.70.8.5357-5362.1996
  contributor:
    fullname: Khanna
SSID ssj0005319
Score 2.0988166
Snippet Abstract Epstein–Barr virus (EBV) latent membrane protein 2A (LMP2A) is a subdominant antigen expressed in EBV-associated malignancies, such as Hodgkin's...
Epstein–Barr virus (EBV) latent membrane protein 2A (LMP2A) is a subdominant antigen expressed in EBV-associated malignancies, such as Hodgkin's diseases (HD)...
Epstein-Barr virus (EBV) latent membrane protein 2A (LMP2A) is a subdominant antigen expressed in EBV-associated malignancies, such as Hodgkin's diseases (HD)...
SourceID proquest
crossref
pubmed
pascalfrancis
fao
elsevier
SourceType Aggregation Database
Index Database
Publisher
StartPage 7414
SubjectTerms Adjuvant
Adjuvants
Allergy and Immunology
Animal models
Animals
antigens
Antigens, Bacterial - immunology
Applied microbiology
Bacteriology
Biological and medical sciences
Cancer
Cancer Vaccines - immunology
Carcinoma
Chaperones
Clinical trials
cytotoxic T-lymphocytes
Cytotoxicity
Cytotoxicity, Immunologic
Epstein-Barr virus
Fundamental and applied biological sciences. Psychology
genetically modified organisms
Heat shock protein 70
Herpes viruses
Herpesvirus 4, Human - immunology
Histocompatibility antigen HLA
Hodgkin disease
Hodgkin Disease - immunology
Hodgkin's disease
HSP70 Heat-Shock Proteins - immunology
Hsp70 protein
Human herpesvirus 4
Humans
Immune response
Immunity
Immunotherapy
Interferon-gamma - biosynthesis
Latent membrane protein 2A
LMP2A protein
Lymphocytes
Lymphocytes T
Malignancy
Melanoma
Membrane proteins
Mice
Mice, Transgenic
Microbiology
Miscellaneous
Multiprotein Complexes - immunology
Mycobacterium tuberculosis
Mycobacterium tuberculosis - immunology
Nasopharyngeal Carcinoma
Nasopharyngeal Neoplasms - immunology
Peptides
Plasmids
Protein folding
Studies
T-Lymphocytes, Cytotoxic - immunology
T-Lymphocytes, Cytotoxic - metabolism
Transgenic mice
Tuberculosis
Tumors
Vaccines
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Viral Matrix Proteins - immunology
Viral Vaccines - immunology
Virology
SummonAdditionalLinks – databaseName: Elsevier ScienceDirect Freedom Collection
  dbid: AIKHN
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb5swFLbaVJv2Mm3ZpWxd5YepT6UxBox5zKpW2SVVpCRV3iwb7ClVG6JAqvJn9lt3zCWomrpJe0uAgw18nHOMv_MZoc-ppyKtQt-VLA7cgKXEVVYZUYWeVSvzTMRsgfP4io3mwbdFuNhD520tjKVVNr6_9umVt262DJq7OVgvl4MpqWI5WUAAs1z2xT46gHBEeQ8dDL9-H111TA-_Wt_DHu9ag66QZ3Bzdi8TO4PdiHlGZ4T5T4WofSMzy52UOdw-U6978XRiWgWoy1foZZNZ4mHd-ddoT6_66Fm91mTZR8_HzSx6H51Mar3q8hTPuvKr_BSf4EmnZA02_WtLlqkqdnFr_gb9skPWlmOQ4oqUrh90jjOD78oEHEQlAA19GU0nEcFyleKLL9f4x3hCh24Ku-7BbG3pNClY6Vs4b9H-d23pp6Uv4aQssiJ7gF8zfFsC6DLYovGmJvWCoT0v4GLpFtu7bIOXVaVLUb5F88uL2fnIbZZ5cBPINQvXaEs2VVZLD9ItHmrOEquqTxM_5UYHvvaJhIG0R40xmsWelLGODTVRKCHDMP471FtlK32IsITRk0qJr4iiQUISldCUcOMnJmapiZWDztonK9a1modoaW43ooGCsFAQJBIABQdF7fMXbakqOFedN296LjyRU0HEH2h0EN9ZPgK0gFj1r0YPAWlC_gQ3L-ZTaj9KwS2C2BI66PgR_HZXQQPGGeOxg45aPIquj0HMCQwcSeQgvNsNfsRODsmVzra54OCJIdv2_3pIbBUrGTTyvkZ617zHIXaEwYf_v-qP6AVt-ZXsCPWKzVZ_goSvUMfNC_0b79xUOw
  priority: 102
  providerName: Elsevier
Title Reconstituted complexes of mycobacterial HSP70 and EBV LMP2A-derived peptides elicit peptide-specific cytotoxic T lymphocyte responses and anti-tumor immunity
URI https://www.clinicalkey.es/playcontent/1-s2.0-S0264410X1101108X
https://dx.doi.org/10.1016/j.vaccine.2011.07.063
https://www.ncbi.nlm.nih.gov/pubmed/21807054
https://www.proquest.com/docview/1498097407
https://search.proquest.com/docview/896395137
https://search.proquest.com/docview/899138269
Volume 29
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lb9NAEF6RViAuCAK0hhLtAfVUp-vX2j6htEoVHokiklS-rdb2LmrVxiF2qvrCT-G3MuNHAoeWSxLHGe_Gnp35dvebGUI-plbsq9hzTMlD13R5yswYMyPGnoXZyiztcwxwHk_4aOF-ibyoWXDLG1plaxMrQ51mCa6RnwKSDxiAX-Z_Wv00sWoU7q42JTQ6ZN8CP4eUvuD8L4qHUxX2gGkGdMNi0S6C5_S6fycT3Lpusnj6fcadh3xTR8sMSZMyh_um64IXDyPSyjNdvCQvGkhJB7UOvCJP1LJLntZFJssueTZuts-75HhaJ6ouT-h8F3eVn9BjOt2lsAaZ7iWyZKpQXdqKvya_ca7akgtSWrHR1b3KaabpbZmAZagyP0NfRrOpz6hcpnR4dkm_jaf2wEzh1B2IrZBHk4KUuoHrFu2xiTGfyFuiSVlkRXYPn-b0pgRty-AbRdc1mxcE8bqgEFdmsbnN1vSqCnEpyjdkcTGcn4_Mpr6DmQDILEytkGUaYxI9wFmBpwKeYDp9O3HSQCvXUQ6TMIO2bK214qElZahCbWvfkwAttPOW7C2zpTokVMK0KU6ZE7PYdhOWxImdskA7iQ55qsPYIP32yYpVncZDtPy2a9GogkBVEMwXoAoG8dvnL9oYVbCqKm-GeC4skduCiRmrICWLAEdhSEVkkGAr2aCYGp0IcFL_a_QQNE3IH2DfxWJm42oU3CJwKp5Bev-o3_Zf2C4POA9Cgxy1-ih2fdwOGoPQ7WkwILgrJJcq2-QiABMMMNt59Cchpqrk0MhBrem75q0AnIbnvnu8-ffkud2SJ_kR2SvWG_UB0FwR90in_8uCVz_ye9Xw7ZH9weevowm8nw0n0-9_AMfJTYs
link.rule.ids 315,783,787,4509,12068,12235,21400,24128,27936,27937,31731,31732,33278,33279,33756,33757,43322,43591,43817,45597,45691,74073,74342,74630
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1bb9MwFLbYEJcXBOWywBh-QHtaOufmJE9ooE0F2qlS2ylvlhPbaNPWlCadlj_Db-WcXBrxsPHWNj2xk5wcf7a_8x1CPisnDXUaeLbksW_7XDE7RWXENHBQrcwxIccE58k5Hy38H0mQtAtuRUur7GJiHahVnuEa-TEg-YgB-GXhl9VvG6tG4e5qW0JjhzxGHS6sYBAmYU_x8OrCHjDNgG44LOkzeI6vhrcyw63rVsUzHDLu3Tc27RiZI2lSFnDfTFPw4n5EWo9MZy_JixZS0pPGB16RR3o5IE-aIpPVgDydtNvnA3I4bYSqqyM67_OuiiN6SKe9hDXYDC6QJVOn6tLO_DX5g3PVjlygaM1G13e6oLmhN1UGkaFWfoa-jGbTkFG5VPT06wUdT6buia3g0C2YrZBHo8BKX8N5y-67jTmfyFuiWVXmZX4Hn-b0ugJvy-EXTdcNmxcM8bzgEJd2ubnJ1_SyTnEpqzdkcXY6_zay2_oOdgYgs7SNRpZpiiJ6gLOiQEc8Qzl9N_NUZLTvaY9JmEE7rjFG89iRMtaxcU0YSIAWxntLdpf5Uu8RKmHalCrmpSx1_YxlaeYqFhkvMzFXJk4tMuyerFg1Mh6i47ddidYVBLqCYKEAV7BI2D1_0eWoQlTVRfuKF8IRhSuYmLEaUrIEcBSmVCQWibaWLYpp0ImAQep_je6Bpwn5C-K7WMxcXI2CWwSDSmCRg3_cb3sVrs8jzqPYIvudP4q-j9uXxiJ0exgCCO4KyaXON4WIIAQDzPYe_EuMUpUcGnnXeHrfvBPBoBH47x9u_hN5NppPxmL8_fznB_Lc7YiUfJ_sluuN_gjIrkwP6tf3L4baS50
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Nb9NAEF3RIiouCAK0hlL2gHqqk_XX2j6hAo0CNFWkJJVvq7W9i1q1doidqv4z_FZm_BGLQ8stiT3ejf129q33zQwhn1Ir9lXsOabkoWu6PGVmjJkRY8_CbGWW9jkGOE8v-GTp_oi8qNU_Fa2ssvOJtaNO8wTfkY-AyQcMyC_zR7qVRcy-jT-vfptYQQp3WttyGjvkKZ6FmPcjv5d7OHWRD1hyQJcsFvXRPKPr4Z1McBu7zejpDxl3HpqndrTMUUApC7iHuil-8TA7rWep8UvyoqWX9LTBwyvyRGUD8qwpOFkNyN603UofkONZk7S6OqGLPgarOKHHdNanswabwSUqZuqwXdqZvyZ_cN3aCQ1SWivT1b0qaK7pbZWAl6izQENfJvOZz6jMUnr25ZKeT2f2qZnCoTswW6GmJgUrdQPXLbvvJsZ_ooaJJlWZl_k9fFrQmwqQl8Mviq4bZS8Y4nUBHFdmubnN1_SqDncpqzdkOT5bfJ2Yba0HMwHCWZpaoeI0xoR6wLkCTwU8wdT6duKkgVauoxwmYTVt2VprxUNLylCF2ta-J4FmaOct2c3yTB0QKmEJFafMiVlsuwlL4sROWaCdRIc81WFskGH3ZMWqSekhOq3btWihIBAKgvkCoGAQv3v-ootXBQ-rina4F8IShS2YmLOaXrIIOBWGV0QGCbaWLaNpmIqACet_jR4A0oT8Bb5eLOc2vpmCWwQTjGeQo3_gt_0XtssDzoPQIIcdHkXfx-0AMgjdHgZngjtEMlP5phABuGOg3M6jp4SYtpJDI_sN0vvmrQAmEM9993jzH8kejFxx_v3i53vy3O40lfyQ7JbrjfoAJK-Mj-rR-xdT5E_V
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Reconstituted+complexes+of+mycobacterial+HSP70+and+EBV+LMP2A-derived+peptides+elicit+peptide-specific+cytotoxic+T+lymphocyte+responses+and+anti-tumor+immunity&rft.jtitle=Vaccine&rft.au=Liu%2C+Genyan&rft.au=Yao%2C+Kun&rft.au=Wang%2C+Bing&rft.au=Zhou%2C+Feng&rft.date=2011-10-06&rft.issn=0264-410X&rft.volume=29&rft.issue=43&rft.spage=7414&rft.epage=7423&rft_id=info:doi/10.1016%2Fj.vaccine.2011.07.063&rft.externalDBID=NO_FULL_TEXT
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F0264410X%2FS0264410X11X00415%2Fcov150h.gif